Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

December 20, 2013

Alterations in specific genes involved in the formation of tissues and organs during embryonic development could be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.

December 16, 2013

A new study has shown a possible correlation between men with short-ended chromosomes in the immune cells of their blood and an increased risk of developing aggressive prostate cancer, potentially pointing the way toward an accessible biomarker that could help inform treatment and surveillance decisions.

December 04, 2013

With seven targeted therapies approved for metastatic renal cell carcinoma, researchers and drug developers are now focusing on understanding the best way to sequence these therapies and on identifying predictive biomarkers of response.

November 27, 2013

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the difficulty of treating a patient with a FLT3-ITD mutation in acute myeloid leukemia (AML).

November 12, 2013

Stephen B. Baylin, MD, is conducting research in his laboratory at Johns Hopkins Medicine that aims to bring epigenetic therapy to the forefront of cancer management, in particular in gaining a better understanding of the abnormalities of chromatin and DNA methylation that may account for the development of epigenetic abnormalities during tumor development.

September 26, 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

September 13, 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, explains the role of PD-1 and PD-L1.

March 07, 2013

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.